Discontinue treatment if serious dermatologic reactions (eg, rash; skin peeling or blistering; lips, eyes or mouth swelling or blistering) are suspected. Interrupt treatment if ALT >3x ULN occurs. Not recommended in patients w/ ischaemic heart disease or CHF. Monitor for signs & symptoms of MI & stroke. Increased frequency of acute gout attacks after initiation of treatment. Increased TSH conc (>5.5 µIU/mL). Consider cardiac monitoring in patients receiving chemotherapy for haematologic malignancies at intermediate to high risk of TLS. Perform LFT (serum ALT, AST, alkaline phosphatase, & total bilirubin conc) prior to initiation of therapy & repeatedly promptly in patients w/ manifestations suggestive of liver damage, eg, fatigue, anorexia, upper right abdominal discomfort, dark-colored urine, or jaundice. Severe hepatic impairment (Child-Pugh class C). Pregnancy & lactation. Childn <18 yr.
Sign Out
